(a virtual meeting)
- Functional assays are critical for lead candidate selection, but are often delayed to secondary and tertiary screening. What are the best ways to implement them in the primary screening process?
- Multiple approaches exist for solubilizing and displaying membrane proteins (liposomes, VLPs, etc) – which ones are generally useful for screening purposes?
- What are the best strategies for improving the sensitivity of fluorescence-based functional assays in nanowell/picowell formats?
Group Leader, Therapeutic Antibody Discovery
John got his Ph.D. from the Scripps Research Institute in 2003. Since then, John’s research has focused on using display technologies, immune approaches and an array of protein engineering approaches for antibody discovery and bi and multispecific antibody engineering at multiple companies – Genentech, Trubion, Emergent BioSolutions, and Novartis. John leads antibody discovery at NIBR in Cambridge, where they use a mix of display and immunization approaches coupled with high throughput screening to find and optimize antibodies for a variety of therapeutic modalities and indications.
- How to overcome the challenges of measuring and quantifying the specific antibody response in your animal or human model?
- What strategies can be implemented to leverage the over-expressed antibodies the animal or human produces naturally as a therapeutic or biomarker?
- How to overcome issues of downstream optimization sooner?
Director, Business Development
Anthony has been heading the business development at Rapid Novor for nearly 4 years, merging his previous 8 years of experience in the business roles with a strong passion for biomedical research, stemming from his training in biomedical engineering. His current efforts are focused on the growth of the REpAb™and NovorIg™ platforms with pharmaceutical and biotech companies globally. His partnerships are focused on using REpAb in patients or animal models to sequence monoclonal antibodies from polyclonal sera, as well as immune system profiling using NovorIg, the team’s NGS based analysis to monitor the relative quantity of specific antibodies over time. Anthony’s a maker and in his spare time takes advantage of the Toronto HackLab to do biological research and other engineering projects.
1:35pm – 2:35pm
- What are the key criteria for selecting an antigen target? What considerations should be taken into account for cancer-associated antigens?
- What are the pros and cons of targeting over-expressed self-antigens, cancer germline antigens, and neoantigens?
- What antibody parameters should be considered when selecting an antigen target? Antibody affinity? Epitope? Internalization rate? Other?
- How does therapeutic modality influence target selection? (i.e. ADC, CAR-T, T-cell engager, conventional mAb)
Senior Director, External Innovation
Johnson & Johnson
Gadi Bornstein has twenty years of experience in Oncology R&D with an emphasis in preclinical antibody discovery and development. In his current role, Gadi has strategic responsibility for scouting and evaluation of external opportunities for collaboration or investment across all biologic drug modalities.
Prior to joining Johnson & Johnson, he led and directed biologics discovery efforts at TESARO, a GSK company. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the University of Southern California Keck School of Medicine. Gadi completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology.
Following his postdoctoral training, Gadi joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology department. He has held roles of increasing responsibility at AstraZeneca, Pfizer, and Novartis, where he was a project team leader and key contributor to scientific strategies for multiple oncology programs. Gadi has authored numerous research papers, reviews, as well as book chapters, and is a co-inventor on multiple patents.